Matches in Wikidata for { <http://www.wikidata.org/entity/Q90358495> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q90358495 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q90358495 description "scientific article published on 01 June 2018" @default.
- Q90358495 description "wetenschappelijk artikel" @default.
- Q90358495 description "наукова стаття, опублікована в червні 2018" @default.
- Q90358495 name "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and R" @default.
- Q90358495 name "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and R" @default.
- Q90358495 type Item @default.
- Q90358495 label "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and R" @default.
- Q90358495 label "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and R" @default.
- Q90358495 prefLabel "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and R" @default.
- Q90358495 prefLabel "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and R" @default.
- Q90358495 P1433 Q90358495-9276260E-6F72-42E8-A759-F9575D6AB826 @default.
- Q90358495 P1476 Q90358495-9046E1F5-14E8-4EC6-81F1-48A767E472D8 @default.
- Q90358495 P2093 Q90358495-3683AF38-9537-4948-92F9-451FB0DD7B15 @default.
- Q90358495 P2093 Q90358495-4F000EC3-1053-401C-8376-37ED97CFFAD6 @default.
- Q90358495 P2093 Q90358495-5932274D-6228-43A1-AF73-0A88E958D772 @default.
- Q90358495 P2093 Q90358495-5A311551-281F-4EF4-9A07-318BF0BA0DED @default.
- Q90358495 P2093 Q90358495-86626A48-47AB-4D8C-9A1F-CF98BBA265BC @default.
- Q90358495 P2093 Q90358495-88A141C8-1B8F-4241-B988-A8323FA3B329 @default.
- Q90358495 P2093 Q90358495-AFF7E9C8-DC4F-4090-8B61-2997F0DEC080 @default.
- Q90358495 P2093 Q90358495-BB8CE036-4FD1-424A-9762-54C2CC37B0CA @default.
- Q90358495 P2093 Q90358495-C8B89107-F246-4418-B54F-CC33F31EC477 @default.
- Q90358495 P2093 Q90358495-CDD12589-AD29-4C09-B277-E52EB0C7BBED @default.
- Q90358495 P304 Q90358495-2B4547E5-3CF3-400F-9D8B-D2C8FF012DBF @default.
- Q90358495 P31 Q90358495-5F80E38B-8896-42AC-BD40-D42668859BFF @default.
- Q90358495 P356 Q90358495-6B4B1383-120C-4353-B640-C79D43C4A523 @default.
- Q90358495 P478 Q90358495-BA440F7C-0DF3-43B6-B55B-B999D1799ACB @default.
- Q90358495 P577 Q90358495-083DFFC2-53BA-4A69-BAF2-C2F64912F715 @default.
- Q90358495 P356 MDY208 @default.
- Q90358495 P1433 Q326122 @default.
- Q90358495 P1476 "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)" @default.
- Q90358495 P2093 "A Zhu" @default.
- Q90358495 P2093 "I Chau" @default.
- Q90358495 P2093 "J F Blanc" @default.
- Q90358495 P2093 "J Llovet" @default.
- Q90358495 P2093 "M Kudo" @default.
- Q90358495 P2093 "P Abada" @default.
- Q90358495 P2093 "P Galle" @default.
- Q90358495 P2093 "R Finn" @default.
- Q90358495 P2093 "T Okusaka" @default.
- Q90358495 P2093 "Y Hsu" @default.
- Q90358495 P304 "v122" @default.
- Q90358495 P31 Q13442814 @default.
- Q90358495 P356 "10.1093/ANNONC/MDY208" @default.
- Q90358495 P478 "29 Suppl 5" @default.
- Q90358495 P577 "2018-06-01T00:00:00Z" @default.